PR Newswire Clinical TrialsOriginal article
Biotech Innovator InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of Worldwide Launch of Non-Injectable Peptide Platform
Non-Injectable Peptide PlatformOral dissolving peptide filmsPositive
AI Analysis
Summary
InstaMed® Pharmaceuticals appointed Tracy Gibbs, PhD as CEO and announced the August 3, 2026 worldwide launch of five next-generation oral dissolving peptide films, supported by successful double-blinded pharmacokinetic study data and nine pending patents.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Product launch of five next-generation oral dissolving peptide films
Importance:5/10
Sentiment:
0.70
peptideoral formulationproduct launchpharmacokinetic studyCEO appointmentpatents pending
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 27, 2026 7:35 PM